EW Healthcare Partners
27.2.2024 21:03:28 CET | ACCESS Newswire | Press release
ORMOND BEACH, FL / ACCESSWIRE / February 27, 2024 / Germfree announces the appointments of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as independent non-executive members of its Board of Directors.
"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors. Their counsel will guide strategic alternatives, aid Germfree in capitalizing on opportunities, and navigate future challenges. Leveraging their collective expertise, the Board will play a pivotal role in driving sustainable growth and ensuring long-term success. Germfree's story is one of relentless innovation, unwavering commitment to quality, and profound impact on global health. We remain committed to advancing innovation and maintaining our position as a leader in critical environment equipment, cleanrooms, and laboratories. Our Board will help Germfree to capitalize on emerging trends and technological advancements, particularly in the rapidly evolving fields of cell and gene therapy," said Kevin Kyle, CEO at Germfree.
Dorothy Puhy brings considerable experience to the Germfree Board and is well-recognized for her financial expertise. She dedicated 25 years to the Dana Farber Cancer Institute, culminating in her role as Executive Vice President and Chief Operating Officer. Prior to that, she was Chief Financial Officer and held various financial positions at the Tufts - New England Medical Center Hospitals. Dorothy served as a Lead Director at Abiomed for c. 20 years, until the successful acquisition of the company by JNJ. As a Lead Director of Abiomed, Dorothy worked closely with the management team and other Board members to set strategic goals and overall direction. In addition to Abiomed, Dorothy served on the boards of BCBS, Azenta and Reebok. She was on the adjunct faculty at Harvard School of Public Health for many years.
Karen Flynn brings more than three decades of commercial and operations experience to the board of Germfree. Most recently, she served as Interim President of BioModalities at Catalent. Preceding this role, Karen held positions as Chief Commercial Officer and President of Biologics at Catalent. Prior to her tenure at Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services, also assuming the role of President of its Pharmaceutical Packaging Systems business. Besides her involvement with Germfree's board, Karen currently holds positions on the Boards of Quanterix Corporation and Sotera Health.
Kerry Ingalls is a pharma veteran who brings experience across manufacturing and operations. He previously served as Chief Operating Officer of Poseida Therapeutics, overseeing corporate strategic planning, operations, and the construction, commissioning, and licensing of the CGT manufacturing plant. Prior to his time at Poseida, Kerry held various leadership positions at Amgen for many years, managing multiple operations sites and overseeing all clinical and commercial GMP manufacturing at Amgen's global headquarters. Before joining Amgen, Kerry had a distinguished career in the US Navy.
Helga Salling presently holds the position of Vice President, Global Growth & Strategy- Life Sciences at Jacobs. With over 20 years of experience in the Life Sciences sector, Helga brings valuable expertise to the Germfree Board. Before joining Jacobs, Helga served as VP Integrated Projects at IPS, and before that, she held positions at DPS Group and served as COO at Advent Engineering.
"We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors. They bring decades of experience, leadership and strategic thinking in key markets that Germfree serves. We are thrilled to be working with them as we aggressively scale the business to meet the needs of our customers, in particular in the cell and gene therapy space," said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.
About Germfree
Germfree has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies.
About EW Healthcare Partners
With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com/
Media Contact
Lauren Blum, Content Marketing Manager at Germfree
+1 386-265-4300
Marketing@germfree.com
www.germfree.com
Contact Information
Lauren Blum
Content Marketing Manager
lblum@germfree.com
+1 386-265-4300
SOURCE: Germfree
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested30.7.2026 21:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 30, 2026 / A new scientific review has found that nutritionally sound vegan dog food, vegan cat food and vegetarian pet diets are generally well digested and broadly comparable to conventional meat-based diets. The review, published in the journal Animals, examined 31 existing studies assessing the digestibility of vegan, vegetarian and plant-based pet diets and ingredients in dogs and cats. Twenty-two studies focused on dogs, two on cats and seven included both species. The review found that across a wide range of study designs, dietary ingredients and digestibility measures, vegan and vegetarian diets consistently showed high digestibility and were not normally significantly less digestible than conventional meat-based diets. Digestibility is an important factor because it indicates how effectively animals can absorb and utilise nutrients from food. While modern commercial plant-based pet foods are generally formulated to provide all essential nutr
Polaris Renewable Energy Announces Q2 2026 Results30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS Second quarter consolidated energy production totaled 199,130 MWh, representing a 8% decrease from 215,797 MWh in the same quarter last year. The decrease was consistent with management's expectations and primarily reflects higher curtailment in the Dominican Republic and the return to normalized hydrological conditions in Peru and Ecuador. The comparative period benefited from exceptionally strong
Polaris Renewable Energy Declares Quarterly Dividend30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 21st, 2026, to shareholders of record at the close of business on August 10th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compa
New GTDC Research Illuminates Distribution's Expanding Role in Modern Technology Ecosystems29.7.2026 15:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / July 29, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, today released a new research report, The Evolving Role of Distribution in Technology Go-To-Market Models, developed in partnership with Channelnomics. The study examines the shift in distribution from a traditional channel intermediary into a strategic operating platform that helps vendors and partners scale, increase support and overcome the complexities associated with innovation (i.e., AI and cybersecurity) and integration. According to the research, customer expectations are rising rapidly as organizations seek integrated outcomes across AI, cybersecurity, hybrid cloud, automation, analytics and managed services. Vendors and partners increasingly struggle to meet those market demands independently with solutions requiring cross-platform integration, multi-vendor coordination, lifecycle support and operational consistency. The G
TIS, EuroFinance Study Finds Corporate Treasurers Actively Evaluating AI, But Hesitant to Adopt It28.7.2026 15:00:00 CEST | Press release
The EuroFinance Deep Dive, supported by Treasury Intelligence Solutions (TIS), interviewed and surveyed corporate treasury leaders, finding that while they see AI as a powerful tool for cash forecasting, multiple concerns are deterring them from adopting it - for now. BERLIN, DE / ACCESS Newswire / July 28, 2026 / Treasury Intelligence Solutions (TIS), a best-in-class solution for payments and cash management, partnered with the research and trade association EuroFinance, in a research initiative that discovered nearly half of leading corporate finance teams are considering the use of artificial intelligence in cash forecasting - but just as many are holding off because of concerns over the technology. The EuroFinance Deep Dive, AI in Treasury: Accuracy, Intelligence and the Future of Cash Forecasting, brings together proprietary research, survey data, and perspectives from treasury leaders at Microsoft, Siemens Energy and other companies to assess where AI is creating value and where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom